Ratetrutide a new generation of weight loss tool Triple Hormone Receptor Agonist GLP-1 Purity 99% 5mg CAS:2381089-83-2

Sales Manager: Lili
Whatsapp: +86 187 1291 7923
Email：lili@lianyi-kj.cn

 Product Detail  

What is Retatrutide ？

Retatrutide is an innovative triple receptor agonist drug developed by Eli Lilly, used for the treatment of type 2 diabetes and obesity. It targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptor (GCGR), regulating blood sugar and metabolism through multiple mechanisms: enhancing insulin secretion, suppressing appetite, delaying gastric emptying, and promoting fat burning. Clinical trials have shown that Retatrutide may be superior to existing GLP-1/GIP dual-targeted drugs (such as tiraglutide) in terms of lowering blood sugar and weight loss. Currently, it is in the III phase of research and is expected to be another major breakthrough in the field of metabolic treatment.

Benefits

1. Rapidly stimulate insulin secretion, precisely lower post-meal blood sugar
(1) Quickly activate pancreatic beta cells, promote insulin release
    Rhetalutide promotes calcium ion influx by closing ATP-sensitive potassium channels in beta cells. Within 30 minutes, it rapidly releases stored insulin, precisely controlling the peak of post-meal blood sugar (peaks within 1-2 hours), and its short-term effect lasts for 4-6 hours to avoid the risk of hypoglycemia before the next meal.
(2) Glucose-dependent regulation, reducing the risk of basal hypoglycemia
    Rhetalutide has glucose-dependent secretion-promoting properties - it strongly stimulates insulin secretion when there is high post-meal blood sugar, and its effect weakens automatically when fasting. Compared to traditional sulfonylureas, it significantly reduces the risk of basal hypoglycemia, especially suitable for the elderly and individuals with glucose sensitivity.

2. Flexible adaptation to diet, improving patients' medication compliance
(1) Take medication with meals, can skip medication if meals are missed, avoiding ineffective medication
    Rhetalutide adopts the "take medication with meals" mode - it is only taken 15 minutes before meals. If there is no meal, it skips the medication. This flexible administration method avoids the risk of hypoglycemia when there is no food intake and adapts to irregular dietary rhythms, significantly improving medication safety and compliance.
(2) Dose can be adjusted as needed, matching different meal calorie contents
    Rhetalutide supports flexible dose adjustment (0.5-4mg per dose). The dosage can be adjusted dynamically based on the calorie content of each meal. The daily dose does not exceed 16mg, achieving precise control of post-meal blood sugar, especially suitable for individuals with irregular diets.

Packing & Transportation

We have professional packaging and shipping services.